Federal Circuit agrees that Exela infringed Ofirmev patents

The US Court of Appeals for the Federal Circuit yesterday (March 23) upheld a district court's decision that pharmaceutical company Exela infringed two patents covering Cadence Pharmaceuticals’s injectable Ofirmev (acetaminophen), used for pain relief.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gene tech firm fends off injunction in test kit dispute

Comparing life sciences IP in Brazil and the US

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

Federal Circuit agrees that Exela infringed Ofirmev patents

Editor's picks

Editor's picks

More features